Betaliq

What Betaliq does

Betaliq, Inc. is a clinical-stage pharmaceutical company founded in 2018 and headquartered in Tarpon Springs, Florida, that develops next-generation topical ophthalmic therapies for glaucoma and ocular hypertension. The company operates a virtual management model with a lean team of 1-10 employees and is led by CEO Barry Butler (formerly Global Category Leader for Pharmaceuticals at Bausch & Lomb and founder/CEO of Sirion Therapeutics), with Novaliq CEO Christian Roesky as Board Chair and Novaliq CFO Oliver Schlüter serving as Betaliq's CFO.

Betaliq's portfolio is built on an exclusive license to Novaliq's EyeSol® technology — described as the worldwide first and only water-free ophthalmic drug delivery platform, using perfluorohexyloctane as the carrier. This addresses fundamental limitations of conventional water-based eye drops (40-50µL drop sizes that exceed ocular capacity, only 1-10% bioavailability, rapid tear clearance) by enabling extended ocular surface retention (minutes to hours), higher bioavailability, preservative-free multi-dose formulation, and minimized systemic exposure. EyeSol® has been clinically validated in over 2,500 patients and is the basis of multiple FDA/EMA-approved products (MIEBO, VEVYE, VEVIZYE, NovaTears). Betaliq's pipeline comprises BTQ1902 (timolol 0.5% suspension in EyeSol® — lead asset, Phase 2a complete, Phase 3 planned after FDA confirmed a single trial suffices for NDA), BTQ2301 (latanoprost in EyeSol®, accelerated development), and BTQ2302 (timolol + latanoprost combination in EyeSol®, accelerated development), each with patent protection.

The company is pre-revenue and funds clinical development through equity capital; it completed an $8 million Series A in 2019 led by Brookline Capital Markets. Upon regulatory approval, Betaliq intends to commercialize through traditional pharmaceutical channels — prescription ophthalmic medications distributed via pharmacies, hospital purchasing, and specialty ophthalmology networks, with future commercialization expected to be supported by ophthalmology-focused field sales teams targeting glaucoma specialists, optometrists, and hospital systems. The company has indicated intent to expand beyond glaucoma into broader ophthalmology and specialty eye care through additional partnerships leveraging the EyeSol® platform.

Name

Betaliq

Legal name

Betaliq Inc.

Website

https://betaliq.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Betaliq is a clinical-stage pharmaceutical company developing next-generation topical glaucoma treatments using Novaliq's exclusive EyeSol® water-free drug delivery platform, targeting the 80M+ global glaucoma patient population through a portfolio of reformulated beta-blockers, prostaglandins, and combination therapies.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industry

Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Ophthalmic pharmaceuticals
• Glaucoma treatments
• Water-free drug delivery
• Topical beta-blockers
• Intraocular pressure therapy

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Betaliq is a clinical-stage pharmaceutical company with no current revenue. Upon regulatory approval of BTQ1902 and future pipeline products, the company expects to generate revenue through the sale of prescription ophthalmic medications for glaucoma treatment. Revenue will come from direct pharmaceutical sales, likely through pharmacy distribution channels and healthcare provider prescriptions.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Betaliq is a clinical-stage pharmaceutical company developing a portfolio of next-generation topical ophthalmic therapies for glaucoma and ocular hypertension, built on Novaliq's proprietary EyeSol® water-free drug delivery platform. The company's pipeline is led by BTQ1902 (timolol 0.5% suspension in perfluorohexyloctane), with additional candidates BTQ2301 (latanoprost) and BTQ2302 (timolol + latanoprost combination) in accelerated development. All products are designed to deliver smaller, preservative-free drops with extended ocular retention, higher bioavailability, and improved tolerability compared to conventional water-based eye drops.

Product overview

Betaliq is a clinical-stage pharmaceutical company developing a portfolio of next-generation topical glaucoma treatments based on its proprietary EyeSol® water-free drug delivery technology. The company's product portfolio consists of three pipeline candidates: BTQ1902 (lead product, timolol 0.5% suspension in perfluorohexyloctane) in Phase 2a completed with Phase 3 planned; BTQ2301 (latanoprost solution in EyeSol®) and BTQ2302 (timolol & latanoprost combination) both in accelerated development. EyeSol® serves as the foundational platform technology licensed from Novaliq that enables improved drug retention, absorption, and tolerability compared to traditional water-based eye drops.

Differentiator

Problem solved

Functional benefit

Products and services

• BTQ1902 Lead clinical-stage drug candidate: timolol 0.5% ophthalmic suspension in perfluorohexyloctane using EyeSol® technology for treatment of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Features >60% smaller drop size at equal efficacy and preservative-free multi-dose formulation. Phase 2a completed; Phase 3 planned.
• BTQ2301 Latanoprost solution formulated with EyeSol® water-free drug delivery technology for treatment of glaucoma; currently in accelerated development stage.
• BTQ2302 Fixed-dose combination therapy combining timolol and latanoprost in EyeSol® water-free formulation for glaucoma treatment; in accelerated development stage.

Quantifiable outcome

• Phase 2a trial demonstrated clinically meaningful IOP reduction with statistical non-inferiority to standard Timolol 0.5%
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Novaliq GmbHcoreTechnology or Integration · 1 January 2018Novaliq GmbH is the developer of the proprietary EyeSol® water-free drug delivery technology. Betaliq was founded in 2018 through a strategic collaboration with BLP Management Group and Novaliq, holding exclusive rights to Novaliq's EyeSol® technology for glaucoma therapies. Novaliq CEO Christian Roesky, PhD serves as Director and Chair of Betaliq's Board, and Novaliq CFO Oliver Schlüter, PhD serves as Betaliq's CFO.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Ocuphire Pharma: Clinical-stage ophthalmic biotech developing Nyxol (phentolamine ophthalmic) for multiple indications including refractive and glaucoma-related conditions. Comparable in size, stage, and clinical focus on novel ophthalmic formulations.
• Qlaris Bio: Clinical-stage ophthalmology biotech developing QLS-111 (atropine-based therapy) for glaucoma. Comparable emerging player with similar stage and focus on differentiated glaucoma mechanisms.
• Kala Bio: Clinical-stage ophthalmic biotech that developed Eysuvis (loteprednol etabonate) for dry eye disease using novel mucus-penetrating particle technology. Comparable clinical-stage ophthalmic specialty company developing differentiated formulations.

Broad incumbents

• Bausch + Lomb: Major ophthalmic pharmaceutical company with established glaucoma portfolio including Vyzulta (latanoprostene bunod, partnered with Nicox). Broad incumbent that could be a strategic acquirer of Betaliq's differentiated glaucoma assets.
• Alcon: World's largest eye care company with extensive glaucoma franchise (Travatan, Azopt, Duotrav, plus acquired Aerie's Rocklatan/Rhopressa). Likely strategic acquirer of differentiated glaucoma assets and uses similar drug-delivery innovation strategy.
• AbbVie (Allergan Aesthetics): Pharmaceutical major owning the Lumigan (bimatoprost), Combigan, and Durysta (bimatoprost implant) franchises for glaucoma. Broad incumbent with established market position that Betaliq would need to differentiate against.
• Santen Pharmaceutical: Japanese specialty ophthalmic pharmaceutical company with major glaucoma franchise (Tapros/tafluprost, Detantol, Cosopt) and active in developing novel ophthalmic formulations. Comparable as specialty ophthalmic player focused on glaucoma therapeutics.

Direct peers

• Aerie Pharmaceuticals: Clinical-stage glaucoma biotech (acquired by Alcon in 2022 for ~$770M) that developed Rhopressa (netarsudil) and Rocklatan (netarsudil/latanoprost combination) for open-angle glaucoma. Most directly comparable company in size, stage, and glaucoma focus to Betaliq.
• Nicox SA: French specialty ophthalmology company that developed VYZULTA (latanoprostene bunod) for glaucoma partnered with Bausch + Lomb. Comparable as a focused ophthalmic pharma developing differentiated glaucoma therapies with novel formulations.

Others

• Novaliq GmbH: Betaliq's technology licensor and developer of the EyeSol® water-free ophthalmic drug delivery platform. Commercial partner with multiple FDA-approved products (MIEBO with Bausch + Lomb, VEVYE). Important relationship as both licensor and adjacent ophthalmic specialty company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/betaliq

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Betaliq